Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Like
Comment
Favorite

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Benzinga05-07

Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.

The company posted quarterly losses of 40 cents per share which beat the analyst consensus estimate of losses of 52 cents per share. The company reported quarterly sales of $392.911 million which beat the analyst consensus estimate of $359.848 million.

Alkermes raised its FY2026 GAAP EPS guidance from $(0.80)-$(0.68) to $(0.52)-$(0.41). The company affirmed FY2026 sales guidance of $1.730 billion-$1.840 billion.

Alkermes shares fell 2.6% to trade at $35.30 on Wednesday.

These analysts made changes to their price targets on Alkermes following earnings announcement.

Needham analyst Ami Fadia maintained Alkermes with a Buy and raised the price target from $45 to $50.
Wells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $43 to $44.

Considering buying ALKS stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2633153690?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 01:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633153690","market":"hk","top_or_hot":-1,"title":"Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results","media":"Benzinga","content":"<html><body><p><strong>Alkermes </strong>(NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.</p>\n<p>The company posted quarterly losses of 40 cents per share which beat the analyst consensus estimate of losses of 52 cents per share. The company reported quarterly sales of $392.911 million which beat the analyst consensus estimate of $359.848 million.</p>\n<p>Alkermes raised its FY2026 GAAP EPS guidance from $(0.80)-$(0.68) to $(0.52)-$(0.41). The company affirmed FY2026 sales guidance of $1.730 billion-$1.840 billion.</p>\n<p>Alkermes shares fell 2.6% to trade at $35.30 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Alkermes following earnings announcement.</p>\n<ul>\n<li>Needham analyst Ami Fadia maintained Alkermes with a Buy and raised the price target from $45 to $50.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $43 to $44.</li>\n</ul>\n<p><strong>Considering buying ALKS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"450\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-1024x450.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-1024x450.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-300x132.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-768x338.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136.png 1230w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlkermes Analysts Increase Their Forecasts Following Strong Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-05-07 01:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Alkermes </strong>(NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.</p>\n<p>The company posted quarterly losses of 40 cents per share which beat the analyst consensus estimate of losses of 52 cents per share. The company reported quarterly sales of $392.911 million which beat the analyst consensus estimate of $359.848 million.</p>\n<p>Alkermes raised its FY2026 GAAP EPS guidance from $(0.80)-$(0.68) to $(0.52)-$(0.41). The company affirmed FY2026 sales guidance of $1.730 billion-$1.840 billion.</p>\n<p>Alkermes shares fell 2.6% to trade at $35.30 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Alkermes following earnings announcement.</p>\n<ul>\n<li>Needham analyst Ami Fadia maintained Alkermes with a Buy and raised the price target from $45 to $50.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $43 to $44.</li>\n</ul>\n<p><strong>Considering buying ALKS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"450\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-1024x450.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-1024x450.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-300x132.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136-768x338.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/06135252/image-136.png 1230w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52336630/alkermes-analysts-increase-their-forecasts-following-strong-q1-results","article_id":"2633153690","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633153690","pubTimestamp":1778090050,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Alkermes reports positive Q1 results, beating expectations. Raises EPS guidance and maintains sales guidance. Analysts raise price targets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALKS":"阿尔凯默斯"},"translate_title":"Alkermes分析师在第一季度业绩强劲后上调预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALKS":1},"content_text":"Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.\nThe company posted quarterly losses of 40 cents per share which beat the analyst consensus estimate of losses of 52 cents per share. The company reported quarterly sales of $392.911 million which beat the analyst consensus estimate of $359.848 million.\nAlkermes raised its FY2026 GAAP EPS guidance from $(0.80)-$(0.68) to $(0.52)-$(0.41). The company affirmed FY2026 sales guidance of $1.730 billion-$1.840 billion.\nAlkermes shares fell 2.6% to trade at $35.30 on Wednesday.\nThese analysts made changes to their price targets on Alkermes following earnings announcement.\n\nNeedham analyst Ami Fadia maintained Alkermes with a Buy and raised the price target from $45 to $50.\nWells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $43 to $44.\n\nConsidering buying ALKS stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}